FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

dc.contributor.author	Kjersem, Janne Beathe
dc.contributor.author	Skovlund, Eva
dc.contributor.author	Ikdahl, Tone
dc.contributor.author	Guren, Tormod Kyrre
dc.contributor.author	Kersten, Christian
dc.contributor.author	Dalsgaard, Astrid Marie
dc.contributor.author	Yilmaz, Mette Karen
dc.contributor.author	Fokstuen, Tone
dc.contributor.author	Tveit, Magne Kjell
dc.contributor.author	Kure, Elin H.
dc.date.accessioned	2015-02-19T09:43:03Z
dc.date.accessioned	2015-02-24T11:11:59Z
dc.date.available	2015-02-19T09:43:03Z
dc.date.available	2015-02-24T11:11:59Z
dc.date.issued	2014
dc.identifier.citation	BMC Cancer 2014, 14
dc.identifier.issn	1471-2407
dc.identifier.uri	http://hdl.handle.net/11250/277437
dc.description	-
dc.language.iso	eng
dc.relation.uri	http://www.biomedcentral.com/content/pdf/1471-2407-14-340.pdf
dc.title	FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
dc.type	Journal article
dc.date.updated	2015-02-19T09:43:03Z
dc.subject.nsi	VDP::Medisinske fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803
dc.subject.nsi	VDP::Midical sciences: 700::Health sciences: 800::Epidemiology, medical and dental statistics: 803
dc.identifier.doi	10.1186/1471-2407-14-340
dc.identifier.cristin	1169120